Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Convertible Debt: 2023

  • Zenas BioPharma's Convertible Debt was N/A to $20.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $20.3 million, marking a year-over-year change of. This contributed to the annual value of $20.3 million for FY2023, which is N/A change from last year.
  • According to the latest figures from Q4 2023, Zenas BioPharma's Convertible Debt is $20.3 million.
  • Zenas BioPharma's 5-year Convertible Debt high stood at $20.3 million for Q4 2023, and its period low was $20.3 million during Q4 2023.
  • In the last 1 years, Zenas BioPharma's Convertible Debt had a median value of $20.3 million in 2023 and averaged $20.3 million.